CVRx

CVRx is a commercial-stage medical device company that developed Barostim, the world's first neuromodulation device for heart failure management — an implantable device that delivers electrical pulses to baroreceptors on the carotid artery to reduce the stress response and improve heart failure symptoms. The company is publicly traded on Nasdaq under the ticker CVRX.